-
USMNT Coaching Search: Guardiola, Cherundolo, and Others Named as Pochettino Replacements
-
North Dakota Enacts Bipartisan Insulin Price Cap Amid National Push
-
Turkish Airlines Launches Fourth Mainland China Route to Chengdu
-
Basil Tuma Scores First Senior Goal as Malta Draws with Ten-Man Eswatini
-
RSC’s ‘Julius Caesar’ Reimagined in Women’s Prison Setting for School Tour
-
Rock & Roll Hall of Fame Inductees Announced; Attendance List Shrinks
-
Thomson Reuters Integrates CUBE Regulatory Intelligence into CoCounsel Legal
-
Xenetic Biosciences Reports Third Quarter 2026 Financial Results and Highlights Strategic Business Updates
-
Does IRS Debt Expire? Clear Start Tax Explains the 10-Year Collection Statute and What Quietly Resets It
-
GameSquare's Hatchet Publishes TikTok Live for Gaming in H1 2026 Report
-
Arrive AI Reports Third Quarter 2026 Results Highlighted by Revenue Growth and Expanded Partnerships
-
Digi Power X Reports Q3 2026 Revenue Up 85% and AI Revenue Up Over 400% Compared to Q2
-
Mako Mining Reports Q3 2026 Financial Results, Including Adjusted EBITDA(1) of US$30.3 million and EPS of US$0.19/share
-
eXoZymes to Host Third Quarter 2026 update Conference Call on Thursday, November 19, 2026
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 13
-
How Families Plan and Save for Holiday Travel
-
Below Deck alumnus João Franco and brother arrested after fatal Turkey fight
-
Ole Miss inquiry expands after video and monkey-noise allegations
-
Thousands of Urban Homes Left Without High-Speed Internet Due to Broadband Blackspots
-
General Hospital actor Randall England dies at 75
-
Bunnie XO artwork taken down from Jelly Roll’s Nashville bar
-
London museum removes Russell Brand hair exhibit after rape conviction
-
Arlington sentinel rebukes Pete Hegseth entourage for laughter near memorial
-
Yella Beezy sentenced to life for arranging rapper Mo3’s murder
-
Kylie Jenner employee describes closet ordeal and pepper-spray incident
-
Authorities to identify Montauk Mary and five other Long Island cold-case victims
-
Davante Adams injury deepens Los Angeles Rams receiver shortage
-
Barbie sequel negotiations stall over reported $25 million pay packages
-
João Franco’s earlier post draws attention after arrest over fatal Turkey brawl
-
Bath & Body Works launches buy-one-get-one-free candle offer
-
Alberta Launches $5M Fund for Women’s Neurology Research to Address Gender Gaps
-
Itlu Arjuna receives U/A certificate ahead of theatrical release
ASP Isotopes and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESS Newswire / April 17, 2025 / RedChip Companies will air interviews with ASP Isotopes Inc. (NASDAQ:ASPI) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, April 19, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Access the interviews in their entirety at:
ASPI: https://www.redchip.com/assets/access/aspi_access.html
BIAF: https://www.redchip.com/assets/access/biaf_access.html
In an exclusive interview, Paul Mann, Chief Executive Officer of ASP Isotopes, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the company's strategic roadmap, breakthrough enrichment technologies, and expanding commercial footprint. Mann will share updates on the Company's three flagship facilities in South Africa: the Carbon-14 plant, which recently began commercial production under a multi-year contract; the Silicon-28 facility, designed to enable next-generation semiconductors for AI and quantum computing; and the Ytterbium-176 plant, which supports advanced radiopharmaceuticals for cancer therapy. These state-of-the-art operations mark ASP Isotopes' evolution from an R&D-stage innovator to a commercial supplier-positioning the Company as a key Western source for critical isotopes in healthcare, semiconductors, and nuclear energy.
Maria Zannes, President and CEO of bioAffinity, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. bioAffinity addresses the urgent need for noninvasive, accurate early-stage cancer diagnosis through its first product, CyPath® Lung. CyPath® Lung improves early-stage detection of lung cancer, leading to increased survival, fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical costs. In October 2024, bioAffinity secured a U.S. Federal Supply Schedule contract for CyPath® Lung, making the test available to U.S. veterans and federal health service patients, which is expected to accelerate sales growth in the quarters ahead.
ASPI and BIAF are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.
About ASP Isotopes, Inc.
ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process ("ASP technology"). The Company's initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum Enrichment technology that the Company is developing. The Company has isotope enrichment facilities in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass (light isotopes).
There is a growing demand for isotopes such as Silicon-28 for enabling quantum computing; Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new, emerging healthcare applications, as well as Chlorine-37, Lithium-6, Lithium-7 and Uranium-235 for green energy applications. The ASP Technology (Aerodynamic Separation Process) is ideal for enriching low and heavy atomic mass molecules.
For more information, please visit www.aspisotopes.com.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
To learn more about RedChip's products and services, please visit:
https://www.redchip.com/corporate/investor_relations
"Discovering Tomorrow's Blue Chips Today"™
Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest
Contact:
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
[email protected]
SOURCE: RedChip Companies, Inc. (Media Suite)
View the original press release on ACCESS Newswire
F.Schneider--AMWN